Better Therapeutics, Inc. Stock price

Equities

BTTX

US08773T1043

Biotechnology & Medical Research

Delayed OTC Markets 11:22:50 2024-03-28 am EDT 5-day change 1st Jan Change
0.0129 USD 0.00% Intraday chart for Better Therapeutics, Inc. -4.44% -93.38%
Sales 2023 * - Sales 2024 * 3.8M Capitalization 703K
Net income 2023 * -28M Net income 2024 * -47M EV / Sales 2023 * -
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 0.19 x
P/E ratio 2023 *
-0.02 x
P/E ratio 2024 *
-0.01 x
Employees 54
Yield 2023 *
-
Yield 2024 *
-
Free-Float 51.23%
More Fundamentals * Assessed data
Dynamic Chart
Better Therapeutics, Inc.(NasdaqCM:BTTX) dropped from S&P TMI Index CI
Better Therapeutics, Inc.(NasdaqCM:BTTX) dropped from NASDAQ Composite Index CI
Sector Update: Health Care Stocks Lower Thursday Afternoon MT
Better Therapeutics to Terminate Employees, Explore Strategic Alternatives; Shares Drop Sharply MT
Better Therapeutics' Platform Targeting Advanced Liver Disease Receives FDA Breakthrough Device Designation MT
Better Therapeutics Gets Breakthrough Device Designation For Cognitive Behavioral Therapy Platform DJ
Better Therapeutics, Inc. Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease CI
Better Therapeutics, Inc. announced that it has received $0.25 million in funding CI
Better Therapeutics Inc. Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx Is More Effective and Less Costly Than Standard of Care Alone CI
Better Therapeutics, Inc. announced that it expects to receive $0.25 million in funding CI
Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States CI
Better Therapeutics Seeks FDA Breakthrough Device Designation for Prescription Digital Therapeutics Targeting Liver Diseases MT
Better Therapeutics, Inc. Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease CI
Better Therapeutics, Inc. Enters into Second Amendment to Loan Agreement with Hercules Capital, Inc CI
Better Therapeutics, Inc. Announces CFO Changes, Effective November 27, 2023 CI
More news
1 week-4.44%
Current month-91.87%
1 month-92.28%
3 months-93.06%
6 months-96.25%
Current year-93.38%
More quotes
1 week
0.01
Extreme 0.0125
0.02
1 month
0.01
Extreme 0.012
0.22
Current year
0.01
Extreme 0.012
0.27
1 year
0.01
Extreme 0.012
1.61
3 years
0.01
Extreme 0.012
29.40
5 years
0.00
Extreme 0
29.40
10 years
0.00
Extreme 0
29.40
More quotes
Managers TitleAgeSince
Chief Tech/Sci/R&D Officer - -
Comptroller/Controller/Auditor 43 21-09-30
Corporate Officer/Principal - 22-10-25
More insiders
Date Price Change Volume
24-03-28 0.0129 0.00% 412 492
24-03-27 0.0129 -5.84% 620,586
24-03-26 0.0137 -21.71% 1,637,871
24-03-25 0.0175 -14.95% 1,121,041
24-03-22 0.0206 +52.41% 2,352,431

Delayed Quote OTC Markets, March 28, 2024 at 11:22 am EDT

More quotes
Better Therapeutics, Inc. is a prescription digital therapeutics (PDT) company. The Company is engaged in developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases. Its lead PDT product candidate, BT-001, is an investigational prescription digital therapy for the treatment of T2D. The investigational therapy is delivered via software that provides a tailored experience to patients designed to help them address the underlying causes of T2D by making meaningful, sustainable behavioral changes. The BT-001 investigational therapy is rooted in the well-studied, gold standard of behavioral modification therapies, cognitive behavioral therapy (CBT). The Company's platform consists of three behavioral therapy, treatment plans and personalization. Its behavioral therapy consists of lessons, skill- building modules, and a mechanism for goal setting. Its treatment plan is the primary engagement interface for patients.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0129 USD
Average target price
1.5 USD
Spread / Average Target
+11,527.91%
Consensus
  1. Stock
  2. Equities
  3. Stock Better Therapeutics, Inc. - OTC Markets